New Drug Approvals Archive
New Drug Approvals: April 2005
| April 7 | Fosamax Plus D (alendronate and cholecalciferol) Tablets Date of Approval: April 7, 2005 Company: Merck & Co., Inc. Treatment for: Osteoporosis Fosamax Plus D is a single once-weekly tablet containing the bisphosphonate drug alendronate, and seven days’ worth of vitamin D, an essential nutrient required for calcium absorption. Fosamax Plus D is used to reduce the risk of hip and spinal fractures in postmenopausal women with osteoporosis, and to increase bone mass in men with osteoporosis. Fosamax Plus D Merck & Co., Inc. - Treatment for Osteoporosis |
| April 28 | Byetta (exenatide) Injection Date of Approval: April 28, 2005 Company: Amylin Pharmaceuticals / Eli Lilly & Co. Treatment for: Diabetes Mellitus Type II Byetta (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Byetta Amylin Pharmaceuticals / Eli Lilly & Co. - Treatment for Type 2 Diabetes |
| November 2 | Byetta (exenatide)
New Indication Approved: November 2, 2009 Byetta Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes |
New Drug Approvals Archive
2009: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Feb | Jul | Aug | Oct | Nov | Dec
